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See related research by Roderburg et al., http://www.ccforum.com/content/19/1/271We embrace with enthusiasm the recent study by
Roderburg et al. [1] identifying osteopontin (OPN) as
a valuable early prognostic biomarker in critically ill
patients. Of note is that these investigators did not
provide details on the incidence of acute kidney in-
jury or the need for renal replacement therapy (RRT)
in their patient population.
We recently argued that currently used markers of sys-
temic inflammation such as C-reactive protein and pro-
calcitonin are substantially cleared during continuous
renal replacement therapy (CRRT) and thus may lose
sensitivity to evaluate the degree and evolution of in-
flammation [2]. OPN is a highly negatively charged pro-
tein. Its nascent molecular weight (MW) approximates
32 kDa with slight variations due to post-translational
modification or proteolytic cleavage [3]. OPN is not
eliminated by slow extended dialysis [4]. This is not* Correspondence: Patrick.Honore@az.vub.ac.be
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off point for molecular diffusion with this technique lies
largely below the MW of OPN. Theoretically, continu-
ous hemofiltration may remove OPN from the cir-
culation but evidence is lacking. Moreover, CRRT is
increasingly performed with novel membranes such as
the surface-treated acrylonitrile 69 membrane [5]. Sur-
face treatment implies coating with a polyethylene imine
biopolymer resulting in a more neutral membrane sur-
face composed of areas with a high density of positive
charges. In addition to being highly biocompatible and
permeable, this membrane displays potent adsorptive
capacity.
More information regarding an eventual significant
“loss” of OPN by filtration and/or membrane adsorption
during CRRT is imperative before this protein can be ac-
cepted as a valid prognostic biomarker.on osteopontin levels in critically ill patients
de, Christian Trautwein, Norbert Frey, Alexander Koch,We are grateful for the letter from Honore et al. rais-
ing the important question of an eventual “loss” of
OPN by filtration during (C)RRT in critically ill pa-
tients. We cannot fully exclude this bias but we have
performed additional analyses on our cohort of critic-
ally ill medical patients [1], suggesting that OPN
serum levels at day 3 after admission to the ICUremain a valuable prognostic biomarker in critically ill
patients. Although the records from our database only
reveal whether patients received RRT or not (and, un-
fortunately, not the exact modalities, time points, and
durations), OPN levels at day 3 were significantly
higher in patients receiving RRT compared with pa-
tients without RRT (Fig. 1a), arguing against ais distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Fig. 1 OPN serum levels are elevated in critically ill patients with RRT. a OPN serum concentrations at day 3 of medical ICU treatment
were significantly higher (P < 0.001, U test) in patients that received RRT (n = 34) compared with patients without need for this therapy
(>n = 78). b, c Patients with a need for RRT displayed a significantly impaired ICU survival and overall survival in comparison with other
patients, based on Kaplan–Meier curve analysis. ***P <0.001. RRT Renal replacement therapy
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nostic role of OPN levels in critically ill patients,
need for RRT (and thus presence of higher OPN
levels) was associated with a dramatically impaired
survival (Fig. 1b, c). Moreover, multivariate analysis
including RRT as a variable revealed that OPN levels
remained an independent prognostic marker in critic-
ally ill patients, as reported previously in our study
[1]. Finally, OPN concentrations were strongly corre-
lated to procalcitonin serum levels, which have been
demonstrated to be independent of RRT in critical
illness [6].
Taken together, our results do not support the concern
that OPN serum levels might not be a valid prognostic
parameter in patients with acute kidney injury undergo-
ing RRT. Nevertheless, we cordially thank Honore et al.
for their valuable comment on our article, as further
prospective trials considering renal failure and replace-
ment should be conducted to properly address this
question.Abbreviations
CRRT: continuous renal replacement therapy; MW: molecular weight;
OPN: osteopontin; RRT: renal replacement therapy.
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